March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
CCR7-amplified Regulatory T Cells Acquire Maximal Lymph Node Homing and Suppress Corneal Allograft Rejection
Author Affiliations & Notes
  • Sunil K. Chauhan
    Department of Ophthalmology, Schepens Eye Research Institute, and Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • Daniel R. Saban
    Department of Ophthalmology, Schepens Eye Research Institute, and Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • Reza Dana
    Department of Ophthalmology, Schepens Eye Research Institute, and Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  Sunil K. Chauhan, None; Daniel R. Saban, None; Reza Dana, None
  • Footnotes
    Support  NIH/NEI R01-12963 and Eye Bank Association of America
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2368. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sunil K. Chauhan, Daniel R. Saban, Reza Dana; CCR7-amplified Regulatory T Cells Acquire Maximal Lymph Node Homing and Suppress Corneal Allograft Rejection. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2368.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Appropriate homing and migration are the pre-requisites for efficient functioning of regulatory T cells (Tregs). We herein investigated whether ex vivo amplification of Treg expression of CC chemokine receptor 7 (CCR7) would facilitate Treg homing to the reactive lymph nodes (LN) and promote corneal allograft survival.

Methods: : Fully disparate corneal grafts from C57Bl/6 (H-2b) mice were orthotopically transplanted onto BALB/c (H-2d) recipient mice. Naïve CD4+CD25+ Tregs (BALB/c) were cultured in a Treg-expansion cocktail (IL2, and CD3/28 Abs) with CCR7 ligand (CCL19 or CCL21). Cultured Tregs were then evaluated for the expression of CCR7, CD62L and CD103 homing receptors using flow cytometry. Tracking dye (PKH26)-labeled CCR7high or CCR7low Tregs were adoptively transferred (2x105 cells/mice) to allograft recipients 24h post-transplantation. Peripheral blood and lymphoid tissues were harvested from allograft recipients at day 4 post-transplantation to identify the homing of labeled Tregs by flow cytometry. Graft survival was evaluated by slit-lamp biomicroscopy weekly up to 10 weeks.

Results: : Tregs cultured in the presence of CCL21, but not CCL19 upregulated Treg expression of CCR7 compared to those in media only. Furthermore, compared to Treg-expansion cocktail only, addition of CCL21 upregulated Treg expression of CCR7 (mean fluorescent intensity, MFI: 301 vs 351) and CD62L (MFI: 132 vs 196), and downregulated expression of CD103 (MFI: 768 vs 319). Adoptive transfer of PKH26-labeled Tregs to allograft recipients showed enhanced LN-homing of CCL21-stimulated CCR7high expressing Tregs (>3-fold in ipsilateral reactive LN) compared to CCR7low Tregs. Only the group that received CCL21-stimulated CCR7high Tregs showed a significant increase in the allograft survival rate (87%, n=8/group, p<0.05). No improvement in graft survival was observed in the recipients which received CCR7low expressing Tregs.

Conclusions: : Our data demonstrate that CCL21 conditioning of Tregs leads to a significant upregulation of CCR7 and CD62L expression, which promotes Treg homing to LN, and downregulation of CD103 which inhibits Treg retention in periphery. These CCL21-treated CCR7high Tregs home more efficiently to the reactive LN of allograft recipients than CCR7low Tregs, and prevent corneal allograft rejection.

Keywords: cornea: basic science • transplantation • immunomodulation/immunoregulation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×